Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-773812 in acute schizophrenia
NCT00259870Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of SB-773812 in schizophrenia (3 arms), sponsored by GSK. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Sep 2005; status: completed.
02
Drugs
SB-773812
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00259870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00259870.